Development of tolerance to clobazam in fully kindled rats: effects of intermittent flumazenil administration

European Journal of Pharmacology
W Löscher, C Rundfeldt

Abstract

The effects of acute and chronic treatment with the 1,5-benzodiazepine, clobazam, were studied on fully kindled amygdaloid seizures in rats. After acute dosing, clobazam significantly reduced all parameters of kindled seizures (seizure severity, seizure duration, duration of amygdalar afterdischarges) at doses of 7.5 or 10 mg/kg i.p. 'Active' plasma concentrations of clobazam ranged between 300-800 ng/ml. The elimination half-life of clobazam in plasma was about 1 h. Only very low (10-75 ng/ml) levels of the major metabolite, N-desmethylclobazam, were detected in rats. Administration of N-desmethylclobazam indicated that plasma concentrations of at least 300 ng/ml were necessary for anticonvulsant effects. During chronic administration of clobazam, 10 mg/kg 3 times daily, marked tolerance developed to the anticonvulsant and adverse (ataxiogenic and sedative) effects of the benzodiazepine. The experiment was repeated using a different protocol with minimized environmental stimuli and no amygdala stimulation during chronic clobazam administration. The loss of effects on seizure severity and motor function was similar to the first chronic experiment, whereas the loss of effects on seizure and afterdischarge duration was less marke...Continue Reading

References

Aug 29, 1989·European Journal of Pharmacology·C A SannerudR R Griffiths
Apr 2, 1985·European Journal of Pharmacology·S F Gonsalves, D W Gallager
Apr 2, 1985·European Journal of Pharmacology·R J Lamb, R R Griffiths
Oct 1, 1988·Trends in Pharmacological Sciences·J R Haigh, M Feely
Jan 1, 1988·Life Sciences·D J Nutt, M J Costello
Jul 1, 1988·Epilepsy Research·A J HellerE H Reynolds
Feb 1, 1987·British Journal of Clinical Pharmacology·J R HaighM Feely
Nov 1, 1985·Experimental Neurology·W Löscher, W S Schwark
Mar 1, 1972·Electroencephalography and Clinical Neurophysiology·R J Racine
Apr 20, 1984·European Journal of Pharmacology·S E Lukas, R R Griffiths
Jan 1, 1983·Pharmacology, Biochemistry, and Behavior·J P PinelG Renfrey
Jun 1, 1983·Therapeutic Drug Monitoring·W Löscher, F J Al-Tahan

❮ Previous
Next ❯

Citations

Mar 31, 1992·European Journal of Pharmacology·C Rundfeldt, W Löscher
Sep 26, 2015·Pharmacological Reviews·Esa R KorpiGavin S Dawe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.